Medicines Co. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
?
M****
?
U****************
?
W******* i* V********
Kontra
?
M************
?
A****************
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 1,50 % | 3,64 % | -11,15 % | -21,98 % | -27,30 % | -35,93 % | -39,07 % |
| Opko Health Inc. | 3,32 % | 1,46 % | 0,21 % | -41,30 % | -10,84 % | -20,07 % | -75,84 % |
| Amicus Therapeutics Inc. | -1,60 % | 1,63 % | 3,31 % | 53,37 % | 4,17 % | 15,55 % | 48,81 % |
Kommentare
News
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) in a February 17, 2026, SEC filing, with an estimated transaction value of $9.31 million